British Drugmaker AstraZeneca has announced to acquire Alexion Pharmaceuticals for Rs $39 billion.
In a filing with the exchange, AstraZeneca said, “The company has agreed to acquire US-based drugmaker Alexion Pharmaceuticals for $39 billion in cash and Shares deal.”
“As a part of the deal Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca American Depository Shares (ADSs) for Alexion Shares,” the filing added.
Speaking on the acquisition deal, Pascal Soriot, Chief Executive of AstraZeneca said, “This acquisition will allow us to enhance our presence in immunology.”
The board of both the companies has approved the deal, which is subject to regulatory and shareholder approval and is expected to close in the third quarter of 2021.
